I'm A Patient
I'm A Provider
Overview
Strong clinical evidence for a dry AMD treatment device can come from a published, peer-reviewed randomized controlled trial with a sham comparator, pre-specified primary endpoints, and validated outcome measures. This design is important because it separates the effect of the active device from the non-specific improvements that result from clinical attention and expectation of benefit.1
MacuMira, an authorized microcurrent therapy device for dry AMD, has a published randomized sham-controlled trial showing statistically significant improvements in both visual acuity and contrast sensitivity in the treatment group. The average gain was 8.2 letters on the ETDRS scale, with 48% of treated patients gaining 10 or more letters. Contrast sensitivity improved by an average of 0.24 log units. The trial recorded no device-related serious adverse events, and more than 21,000 real-world treatments since launch have also had none.2
Why Evidence Quality Matters
Dry AMD is a slowly progressive condition that affects central vision over a long period, sometimes months or decades. Patients managing it face a long-term treatment relationship and meaningful decisions about how to allocate their time and financial resources. Therefore, the evidence behind any treatment they consider should be robust enough to justify those decisions.3
That standard is not always met. The term “dry AMD treatment” is applied to a range of products and services, from regulated medical devices with published clinical trials to wellness products and unregistered devices that have not been assessed by any regulatory authority. Marketing materials, patient testimonials, or claims of clinical benefit do not substitute for a peer-reviewed trial.
For clinicians, the evidence standard required before recommending a device to patients should be at least as rigorous as the standard applied to any other clinical decision. A device that is approved by a recognized regulatory authority and supported by a randomized controlled trial provides a defensible basis for a clinical recommendation. A device without that standard does not, regardless of how plausible its mechanism sounds.1
Types of Evidence
Randomized Sham-Controlled Trial
A randomized controlled trial with a sham comparator is a rigorous study design for evaluating a medical device. Patients are assigned randomly to either the active device or a sham procedure that mimics the real treatment in all observable respects except the active component. Randomization distributes known and unknown confounding factors equally between groups, and the sham control accounts for the expectation effect that is particularly strong in device studies.1
Pre-specified primary endpoints are another critical quality marker. When outcomes are defined before data collection begins, there is no opportunity to selectively report endpoints that happened to show improvement. Studies that define their primary endpoints after looking at the data, sometimes called outcome switching, can produce misleadingly positive results.
Independent statistical analysis and full adverse event reporting complete the picture. A trial that reports only positive outcomes without a clear account of what happened to all enrolled patients, including those who did not complete the study or who experienced adverse events, cannot be fully evaluated.
Observational Studies and Case Series
Observational studies and case series can generate useful hypotheses and provide early signals about whether a treatment is worth investigating in a controlled trial. They are not, however, an adequate evidence base on their own for recommending a treatment to patients. Without randomization and a control group, it is not possible to determine whether observed improvements are caused by the treatment or by other factors, including natural variation in disease course and expectation effects.1
Some device manufacturers present observational data as if it were equivalent to randomized trial evidence. It is not. When reviewing such data, note what it does and does not show, and ask whether a controlled trial has been conducted or is underway.
Regulatory Authorization
Regulatory authorization from a recognized authority, such as Health Canada, the FDA, or Australia’s TGA, is an important factor to consider. This is a necessary threshold for clinical use, but it does not, by itself, tell a clinician or patient how strong the evidence is or how confident they can be about expected outcomes.4
Multiple devices may both hold regulatory approval while differing substantially in the strength of their supporting evidence. One may be backed by a large randomized trial; another may have been approved based on a smaller or less rigorously controlled study. To understand what the data actually show, review the primary evidence rather than stopping at the fact of approval.
The MacuMira Clinical Trial
MacuMira’s published clinical evidence comes from a randomized sham-controlled trial designed to assess the effect of low-level electrical microcurrent stimulation on visual function in patients with dry AMD. The trial enrolled patients with best-corrected visual acuity between 20/50 and 20/200, a range corresponding to mild to moderate visual impairment from dry AMD. The primary outcome measures were ETDRS visual acuity and contrast sensitivity, both of which reflect clinically meaningful aspects of visual function in daily life.2
Visual Acuity
In the treatment group, best-corrected visual acuity improved significantly over the treatment period. The average gain was 8.2 letters on the ETDRS scale. To provide context, a gain of 15 or more letters is conventionally considered a large and clinically significant improvement in AMD trials; a gain of 5 to 14 letters represents a meaningful functional benefit. With 48% of treated patients gaining 10 or more letters, the outcome distribution was weighted toward the clinically meaningful range.2
The sham group, which received a procedure identical in all observable respects except for the active electrical stimulation, did not show the same pattern of improvement. This comparison is what allows the trial to attribute the visual acuity gains to the active treatment rather than to expectation of benefit or natural variation.2
Contrast Sensitivity
Contrast sensitivity, the ability to distinguish objects from their background at varying levels of contrast, is frequently reduced in dry AMD independently of high-contrast visual acuity. A patient whose ETDRS acuity score appears relatively preserved may still struggle to read in low lighting, recognize faces or navigate environments with variable contrast. Measuring contrast sensitivity alongside acuity therefore captures a dimension of visual function that is highly relevant to daily life.3
In the MacuMira trial, contrast sensitivity improved by an average of 0.24 log units in the treatment group. This improvement, alongside the visual acuity gains, supports the interpretation that the treatment was affecting multiple aspects of visual function rather than a single narrowly measured endpoint.2
Safety Outcomes
No device-related serious adverse events were recorded in the clinical trial. This safety record has been maintained in real-world use, with more than 21,000 treatments delivered across hundreds of clinics in 3 countries since launch and no device-related serious adverse events reported. For a relatively new device category, this post-market safety record provides meaningful reassurance beyond what the trial population alone could demonstrate.2
Eligibility Range
The trial enrolled patients with visual acuity between 20/50 and 20/200. This range is important for interpreting the results in clinical practice. Patients whose baseline acuity is better than 20/50 are not well represented in the trial population and may experience a ceiling effect. This does not mean such patients cannot benefit, but the evidence for patients outside the studied range is extrapolated rather than direct.2
Patients with wet AMD were excluded from the trial and are excluded from the approved indication. The evidence for dry AMD does not apply to wet AMD.
Understanding the Evidence
The MacuMira trial evidence supports the claim that the device improves visual function, specifically visual acuity and contrast sensitivity, in dry AMD patients within the studied eligibility range. This is the authorized indication: To improve visual function in patients with dry AMD.2
The evidence does not support claims about slowing AMD progression, preventing vision loss or producing outcomes that generalize to all AMD patients regardless of disease stage or baseline acuity. These are different clinical claims requiring different evidence. Clinicians and patients should be cautious about any characterization of device-based therapy that goes beyond what the published evidence demonstrates.1
Understanding this distinction matters for how the therapy is presented to patients. A patient who is told the therapy will improve their vision and experiences a meaningful gain has had an accurate expectation met. A patient who is told it will stop their AMD from progressing has been given an expectation the evidence does not support and may feel misled if their disease continues to develop structurally even while their functional vision improves.
How to Evaluate Evidence as a Patient or Clinician
- Ask whether a peer-reviewed randomized controlled trial has been published. A manufacturer summary document is not equivalent to the primary publication.1
- Check whether the trial used a sham control rather than a no-treatment or wait-list comparison. Sham control is an appropriate design for device trials.1
- Ask whether the primary endpoints were pre-specified before the trial began or defined after the data were collected.
- Review the outcome measures. ETDRS visual acuity and contrast sensitivity are validated and clinically meaningful. Subjective patient-reported outcomes alone are not sufficient.1
- Look at the full adverse event record, not just the headline safety statement. A claim of zero adverse events should be verifiable from the trial publication.2
- Ask about post-market data. How many treatments have been delivered since launch? Has any adverse event data been submitted to the relevant regulatory authority?2
- Consider whether the trial population matches your own situation or patient population. Evidence from a specific acuity range does not automatically generalize to patients outside that range.
Conclusion
The strongest clinical evidence for a dry AMD treatment device is a published randomized sham-controlled trial with pre-specified endpoints, validated outcome measures and full adverse event reporting. MacuMira’s published trial meets this standard, showing statistically significant improvement in visual acuity and contrast sensitivity in the treatment group, with an average gain of 8.2 ETDRS letters and a 0.24 log unit improvement in contrast sensitivity and zero device-related serious adverse events in both the trial and more than 21,000 subsequent real-world treatments. The evidence supports improvement in visual function in eligible dry AMD patients. It does not support claims that it slows AMD progression. Patients and clinicians should read the primary publication rather than relying on summaries and should evaluate any device against the evidence standards described in this article.
Disclaimer
This article is for educational purposes only and does not constitute medical advice. Patients and clinicians should review primary published evidence when evaluating any treatment and consult a qualified eye care professional before making treatment decisions.
Glossary
ETDRS scale: The Early Treatment Diabetic Retinopathy Study visual acuity scale, scored letter by letter. The standard outcome measure in AMD clinical trials.
Contrast sensitivity: The ability to distinguish objects from their background at varying contrast levels. Frequently reduced in dry AMD independently of high-contrast visual acuity. Measured in log units.
Sham-controlled trial: A clinical trial in which the control group receives a procedure mimicking the active intervention in all observable ways except the active component. The appropriate comparator for device efficacy trials.
Randomized controlled trial (RCT): A study design in which participants are randomly assigned to treatment or control groups. Randomization distributes confounding factors equally and allows causal conclusions about treatment effects.
Pre-specified endpoints: Outcome measures defined before data collection begins. Pre-specification prevents selective reporting of only those outcomes that happened to show improvement.
MacuMira: An approved medical device indicated to improve visual function in patients with dry AMD, delivered via low-level electrical stimulation in a clinical setting under the supervision of a licensed eye care professional. Not indicated for wet AMD.
Ceiling effect: In clinical measurement, the limited scope for improvement when a patient’s baseline function is near the upper end of the measurement scale.
Dry AMD: A progressive retinal condition affecting the macula. The most common form of AMD. Distinct from wet AMD in pathophysiology and clinical management.
Wet AMD: A form of AMD involving abnormal blood vessel growth beneath the retina. Treated with anti-VEGF injections. The MacuMira trial excluded wet AMD patients and the device is not indicated for wet AMD.
Post-market surveillance: Ongoing monitoring of a device’s safety and performance after regulatory approval through adverse event reporting and real-world outcome tracking.
Health Canada Medical Device Licence: Regulatory authorization confirming a medical device meets Canadian safety and efficacy standards for its approved indication.
References
1. Understanding Macular Degeneration. American Academy of Ophthalmology. Published November 2025. Accessed June 2026. https://www.aao.org/eye-health/diseases/amd-macular-degeneration.
2. Evaluation of visual acuity in dry AMD patients after microcurrent electrical stimulation. Parkinson KM, Sayre EC, Tobe SW. International Journal of Retina and Vitreous. Published May 2023. Accessed June 2026. https://macumira.com/wp-content/uploads/2025/07/MacuMira-Clinical-Trial.pdf.
3. Age-Related Macular Degeneration. National Eye Institute, National Institutes of Health. Last reviewed November 2023. Accessed June 2026. https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/age-related-macular-degeneration.
4. Medical Device Licences. Health Canada. Date not listed. Accessed June 2026. https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/licences.html.
5. Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration: The Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial. AREDS2 Research Group. JAMA. Published May 15, 2013. Accessed June 2026. https://jamanetwork.com/journals/jama/fullarticle/1684847.
